Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05684133 · ClinicalTrials.gov registry record
REMISE Study: REMnant Biospecimen Investigation in SEpsis
A clinical trial of Sepsis, sponsored by University of Pittsburgh.
- Completed
- Registry status
- 71
- Enrollment target
- 1
- Study location
NCT05684133: Completed study of Sepsis, sponsored by University of Pittsburgh.
NCT05684133 is a study of Sepsis that has completed, run by University of Pittsburgh. The registered enrollment target is 71 participants, below the 6,564-participant average among 90 other Sepsis trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05684133, a study of Sepsis, has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- 71 participants
- Enrollment target
- 1
- Study location
Study Summary
In the REMISE is study, we will compare blood proteins, biomarkers, and other -omics prospectively collected from patients with sepsis from two sources, i.) remnant (discarded) samples from the clinical laboratory, and ii.) prospectively collected in UPMC Presbyterian hospital research coordinator specimen collected biospecimens. Analyses will include traditional biomarkers, quantitative proteomics, metabolomics, lipidomics, transcriptomics, and pathogen genomic sequencing in both sets of samples. This data will allow the assessment of the feasibility, integrity, and scientific value of remnant samples compared to research coordinator samples collected at the bedside for mechanistic sepsis research.
Conditions Studied
Study Locations (1)
Pennsylvania
- University of Pittsburgh - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 71 participants |
| Start Date | 2022-10-25 |
| Est. Completion | 2023-12-31 |
What the finished NCT05684133 record still lists
NCT05684133 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 71 participants, a relatively small participant target, below the 6,564-participant average among 90 other Sepsis trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Sepsis appearing as the primary indexed condition, and to 0 interventions.
NCT05684133 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05684133 about?
NCT05684133 is a clinical study titled "REMISE Study: REMnant Biospecimen Investigation in SEpsis". In the REMISE is study, we will compare blood proteins, biomarkers, and other -omics prospectively collected from patients with sepsis from two sources, i.) remnant (discarded) samples from the clinical laboratory, and ii.) prospectively collected in UPMC Presbyterian hospital research coordinator s...
What is the current status of trial NCT05684133?
This trial is currently completed. The enrollment target is 71 participants. The study started on 2022-10-25. Estimated completion is 2023-12-31.
What conditions does trial NCT05684133 study?
This clinical trial studies the following conditions: Sepsis.
Who is sponsoring clinical trial NCT05684133?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05684133 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sepsis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05684133's enrollment target sits among peer trials
71 65th of 90 higher than 26 of 90 other Sepsis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sepsis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The APS Phenotyping Study
RECRUITING
-
Senolytics To slOw Progression of Sepsis (STOP-Sepsis) Trial
RECRUITING · Phase 2
-
Early Versus Late Adjunctive Vasopressin in Septic Shock
RECRUITING · Phase 4
-
Renin Angiotensin Aldosterone System In Septic Kids
RECRUITING
-
The RightCall: Implementing a Sepsis Diagnostic Toolkit to Improve Pediatric Diagnosis in ED Transfer Calls
RECRUITING · NA
-
External Drainage of Thoracic Duct Lymph to Reduce Inflammatory Cytokines in Septic Shock Patients
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05452889 · 71 participants · Early Phase 1
PET Image in PAH Patients
- NCT05766943 · 71 participants · NA
Reduction of Myopotential Interference With Smart Pass in S-ICD Patients
- NCT06229678 · 71 participants · Early Phase 1
Ketones, SGLT2, HFrEF
- NCT06377566 · 71 participants · Phase 2
A Study of BV-AVD in People With Bulky Hodgkin Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI